Market revenue in 2023 | USD 0.3 million |
Market revenue in 2030 | USD 0.8 million |
Growth rate | 16.8% (CAGR from 2023 to 2030) |
Largest segment | Cell & gene therapy |
Fastest growing segment | Immunotherapy |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Cell & Gene Therapy, Immunotherapy |
Key market players worldwide | Charles River Laboratories International Inc, Boehringer Ingelheim, Thermo Fisher Scientific Inc, Lonza Group Ltd, Viva Biotech, VGXI, PlasmidFactory, BioCina, TriLink BioTechnologies, Esco Aster |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to plasmid dna contract manufacturing market will help companies and investors design strategic landscapes.
Cell & gene therapy was the largest segment with a revenue share of 66.67% in 2023. Horizon Databook has segmented the Kuwait plasmid dna contract manufacturing market based on cell & gene therapy, immunotherapy covering the revenue growth of each sub-segment from 2018 to 2030.
The growth of the market in the country is low as compared to other MEA countries. The key factors driving the market are rising geriatric population and increasing prevalence of chronic diseases. Geriatric population results in social and economic burden.
According to a recent analysis by CSR GULF, Kuwait would have aging demography by 2040 if fertility rates continue to drop along with the high percentage of celibacy. According to data from the Public Authority for Civil Information, the population of Kuwait shrank from 3.3% in 2011 to roughly 2.0% in 2020 and then to 1.8% in 2021.
On the other hand, the population of those aged 65 and over rose from 2.0% in 2011 to roughly 4.0% by the end of 2021. These abovementioned factors would drive the need for plasmid DNA contract manufacturing market in the country.
Horizon Databook provides a detailed overview of country-level data and insights on the Kuwait plasmid dna contract manufacturing market , including forecasts for subscribers. This country databook contains high-level insights into Kuwait plasmid dna contract manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account